Rita. This deviation will allow Federal agencies to purchase premium gasoline for government owned and leased vehicles when lower grade gasoline is not available. This deviation can be found at www.gsa.gov/vehiclepolicy and clicking on ''Deviation from 41 CFR 102–34.335''.

**DATES:** The deviation announced in this notice is effective September 8, 2005.

**FOR FURTHER INFORMATION CONTACT:** For clarification of content, contact General Services Administration, Office of Governmentwide Policy, Office of Travel, Transportation and Asset Management, at (202) 501–1777 and cite the deviation regarding motor vehicle management dated September 30, 2005.

**SUPPLEMENTARY INFORMATION:**

### A. Background

Federal Management Regulation (FMR) section 102–34.335 (41 CFR 102–34.335) prohibits the use of premium grade gasoline in any motor vehicle owned or leased by the Government unless the motor vehicle specifically requires premium grade gasoline. This section states that drivers are to use the grade (octane rating) of gasoline recommended by the motor vehicle manufacturer when fueling motor vehicles owned or leased by the Government.

As a result of the catastrophic destruction caused by Hurricanes Katrina and Rita, agencies have reported that their vehicles operators are unable to purchase lower octane gasoline for their vehicles to complete their missions. In many areas, agencies have only been able to procure premium gasoline for use in their motor vehicles. The original intent of section 102–34.335 was to reduce fuel costs and eliminate the unnecessary use of premium gasoline in vehicles capable of being operated on lower grade gasoline.

A notice announcing this deviation was published in the **Federal Register** on September 16, 2005 (70 FR 54747) as a result of Hurricane Katrina. This notice amends that notice by including all agencies whose purchase of gasoline for motor vehicles has been impacted by both Hurricanes Katrina and Rita.

### B. Procedures

This deviation is located on the Internet at *www.gsa.gov/vehiclepolicy* and clicking on ''Deviation from 41 CFR 102–34.335''.

Dated: September 30, 2005.

**Becky Rhodes,**

*Deputy Associate Administrator.*

[FR Doc. 05–20375 Filed 10–11–05; 8:45 am]

**BILLING CODE 6820–14–S**

## GENERAL SERVICES ADMINISTRATION

**Federal Travel Regulation (FTR)**

### Maximum Per Diem Rates for Florida and Ohio

**AGENCY:** Office of Governmentwide Policy, General Services Administration (GSA).

**ACTION:** Notice of Per Diem Bulletin 06–2, revised continental United States (CONUS) per diem rates.

**SUMMARY:** The General Services Administration (GSA) is making a technical correction to the lodging rates of certain locations in the States of Florida and Ohio. The per diems prescribed in Bulletin 06–2 may be found at *www.gsa.gov/perdiem.*

**DATES:** This notice is effective [enter date of publication in the **Federal Register**] and applies to travel performed on or after October 1, 2005.

**FOR FURTHER INFORMATION CONTACT:** For clarification of content, contact Lois Mandell, Office of Governmentwide Policy, Travel Management Policy, at (202) 501–2824. Please cite FTR Per Diem Bulletin 06–2.

**SUPPLEMENTARY INFORMATION:**

### A. Background

After an analysis of the per diem rates established for FY 2006 (see the **Federal Register** notices at 70 FR 52100, September 1, 2005), a technical correction is being made to the per diem rates in the following locations:

*State of Florida*

- Brevard County

*State of Ohio*

- Cuyahoga County

### B. Procedures

Per diem rates and the FTR Per Diem Bulletin are published on the Internet at *www.gsa.gov/perdiem.* A Federal Notice is published in the **Federal Register** on a periodic basis. This process ensures timely increases or decreases in per diem rates established by GSA for Federal employees on official travel within CONUS. Notices published periodically in the **Federal Register**, such as this one, now constitute the only notification of revisions in CONUS per diem rates to agencies.

Dated: October 5, 2005.

**Rebecca Rhodes,**

*Deputy Associate Administrator.*

[FR Doc. 05–20374 Filed 10–11–05; 8:45 am]

**BILLING CODE 6820–14–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Toxic Substances and Disease Registry

### Statement of Organization, Functions, and Delegations of Authority

Part T (Agency for Toxic Substances and Disease Registry) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (50 FR 25129–25130, dated June 17, 1985, as amended most recently at 69 FR 60629, dated October 12, 2004) is amended to reflect the reorganization of the Agency for Toxic Substances and Disease Registry (ATSDR).

Section T–B, Organization and Functions, is hereby amended as follows:

Delete in its entirety the functional statements for the *Division of Health Studies (TB8),* and insert the following:

*Division of Health Studies (TB8).* (1) Coordinates all activities associated with human health studies, surveillance activities, and registries; (2) provides medical epidemiologic, and biostatistical assistance and consultation; (3) implements extramural research programs that involve human health investigations.

*Office of the Director (TB81).* (1) Plans, directs, coordinates, and manages the operations of the Division of Health Studies; (2) develops goals and objectives and provides leadership, policy formulation, and guidance in program planning and development; (3) facilitates the science, including analytic support of the division and undertakes special scientific activities; (4) coordinates division activities with other components of ATSDR and other federal agencies.

*Surveillance and Registries Branch (TB82).* (1) Designs and conducts surveillance and registry programs to evaluate the adverse health effects on persons exposed to hazardous substances; (2) conducts health follow-up activities resulting from surveillance and registries; (3) implements extramural research programs that involve surveillance and registries.

*Health Investigations Branch (TB84).* (1) Designs and conducts human health, including epidemiologic, studies to evaluate the association between exposure to hazardous substances and adverse health effects; (2) provides expert medical and environmental epidemiologic consultation; (3) implements extramural research programs that involve human health investigations.

Dated: June 3, 2005.

**William H. Gimson,**

*Chief Operating Officer, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 05–20369 Filed 10–11–05; 8:45 am]

**BILLING CODE 4160–70–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Advisory Committee on Immunization Practices

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal Committee meeting.

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Times and Dates:*

8:30 a.m.–5:15 p.m., October 26, 2005.
8 a.m.–3:30 p.m., October 27, 2005.

*Place:* Atlanta Marriott Century Center, 2000 Century Boulevard, N.E., Atlanta, Georgia 30345–3377.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 United States Code 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

*Matters to Be Discussed:* The agenda will include discussions on influenza; recommendations for use of Hepatitis A vaccine among children; VFC vote on Hepatitis A; adult Hepatitis B vaccine recommendation; varicella zoster immune globulin; recommended childhood and adolescent immunization schedules; use of Tdap vaccine; prevention of rotavirus gastroenteritis; Measles, Mumps, Rubella Vaccine (MMRV) recommendation; VFC vote on MMRV; Human Papailloma Virus vaccine; general recommendations on immunization; herpes zoster; and Departmental updates.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., (E–61), Atlanta, Georgia 30333, telephone 404/639–8096, fax 404/639–8616.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: October 5, 2005.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 05–20381 Filed 10–11–05; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2005N–0393]**

### Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Regulations

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on requirements under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted.

**DATES:** Submit written or electronic comments on the collection of information by December 12, 2005.

**ADDRESSES:** Submit electronic comments on the collection of information to:*http://www.fda.gov/dockets/ecomments*. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Karen Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

**Investigational New Drug Regulations—21 CFR Part 312 (OMB Control Number 0910–0014)—Extension**

FDA is requesting OMB approval for the reporting and recordkeeping requirements contained in the FDA regulation ''Investigational New Drug Application'' in part 312 (21 CFR part 312). This regulation implements provisions of section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) to issue regulations under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted.

FDA is charged with implementing statutory requirements that drug products marketed in the United States be shown to be safe and effective, properly manufactured, and properly labeled for their intended uses. Section 505(a) of the act provides that a new drug may not be introduced or delivered for introduction into interstate commerce in the United States unless FDA has previously approved a new drug application (NDA). FDA approves